Zenas BioPharma’s (ZBIO) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a report released on Friday,Benzinga reports. The firm currently has a $55.00 price target on the stock.

ZBIO has been the subject of several other reports. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a report on Friday. Morgan Stanley increased their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zenas BioPharma currently has a consensus rating of “Moderate Buy” and an average target price of $45.71.

Zenas BioPharma Trading Up 1.1%

Shares of Zenas BioPharma stock opened at $29.51 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. Zenas BioPharma has a 1 year low of $13.50 and a 1 year high of $44.60. The firm has a market cap of $1.86 billion, a PE ratio of -3.28 and a beta of -1.03. The company has a 50 day simple moving average of $26.95 and a two-hundred day simple moving average of $23.38.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. Analysts expect that Zenas BioPharma will post -4.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the stock in a transaction on Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the purchase, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. SR One Capital Management LP grew its position in Zenas BioPharma by 2.6% during the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after acquiring an additional 126,315 shares during the last quarter. NEA Management Company LLC raised its holdings in Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares during the last quarter. Federated Hermes Inc. boosted its position in Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after buying an additional 853,740 shares during the period. BlackRock Inc. purchased a new stake in Zenas BioPharma during the 2nd quarter valued at $68,176,000. Finally, Vanguard Group Inc. grew its holdings in Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after acquiring an additional 290,307 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.